Herpes simplex - I-Herpes Simplex
☆ Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
I-Herpes simplex emlonyeni.
I-Herpes Simplex (Herpes simplex) ― Ukutheleleka nge-Herpes simplex eminweni kuvame kakhulu ezinganeni ezincane kunabantu abadala.
References
Ukutheleleka kwe-HSV-1 kuqhubeka ngokutheleleka okuyinhloko kwamaseli e-epithelial, kulandelwa ukubambezeleka, ikakhulukazi kuma-neuron, kanye nokwenza kusebenze kabusha. I-HSV-1 ivamise ukubangela ukuqhuma kwe-vesicular kokuqala nokuphindaphindayo, ikakhulukazi emlonyeni kanye nolwelwesi lwesitho sangasese. Ukubonakaliswa kwayo kusuka ku-herpes ye-orolabial kuya ezimeni ezihlukahlukene ezifana ne-herpetic folliculitis, izifo zesikhumba, ukubandakanyeka kwe-ocular, kanye nezimo ezinzima njenge-herpes encephalitis. Ukwelashwa ngama-antiviral kusiza ukuphatha ukutheleleka kwe-HSV.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 2 (HSV-2) ukutheleleka okusabalele, okuthinta cishe ama-22% abantu abadala abaneminyaka engu-12 nangaphezulu, ingqikithi yabantu abadala abayizigidi ezingu-45 e-United States. Nakuba i-HSV-1 ngokuvamile ibangela izilonda zomlomo, ingase futhi ibangele izilonda ezithweni zangasese. Kodwa-ke, lapho iziguli zinezilonda ezithweni zangasese, i-HSV-2 ivame ukukhathazeka kakhulu. Izimpawu zokuqubuka kwe-HSV-2 zivame ukungacaci, njengokuluma kwesitho sangasese kanye nokucasuka, okungabambezela ukuxilongwa nokwelashwa. Lokhu kubambezeleka kungase kuphumele ekudluliseleni okwengeziwe kubantu abangenalo igciwane.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus (HSV) kuvame ukubangela izifo ezifana ne-genital herpes kanye nezilonda ezibandayo entsheni nakubantu abadala. Uma i-HSV ithelela usana emasontweni okuqala angu-4-6 okuphila, kungaholela ekuguleni okukhulu okunemiphumela emibi kakhulu. Ukuxilonga ngokushesha ukutheleleka kwe-HSV yezingane ezisanda kuzalwa kubalulekile ukuze kunqandwe lesi sifo ukuthi singabi sibi kakhulu, kuvinjwe izinkinga zezinzwa (ngisho nokufa) .
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex ukutheleleka kuvame kakhulu futhi kungadluliselwa kusuka kwabesifazane abakhulelwe kuya ezinganeni zabo. Leli gciwane lingabangela izinkinga zempilo ezingathi sína noma ngisho nokufa kwezingane ezisanda kuzalwa. Nakuba kungavamile ngesikhathi sokukhulelwa ngokwakho, ngokuvamile kwenzeka ngesikhathi sokubeletha. Ingozi inkulu kakhulu uma umama etheleleka ezigabeni zakamuva zokukhulelwa. Kodwa-ke, le ngozi ingancishiswa ngokusebenzisa imishanguzo ye-antiviral noma ukukhetha i-C-section ezimweni ezithile.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Herpes simplex virus (HSV) izinhlobo 1 no-2 zithelela abantu abaningi emhlabeni jikelele. Ngokuvamile, igciwane lihlala lithule kumangqamuzana ezinzwa ngemva kokuthelela isikhumba, kodwa lingase liphinde lisebenze kamuva, libangele izilonda ezibandayo. Kwesinye isikhathi, kuholela ezinkingeni ezinzima njengokutheleleka kwamehlo, ukuvuvukala kobuchopho, noma izimo eziyingozi ezinganeni ezisanda kuzalwa kanye nabantu abanamasosha omzimba abuthaka. Nakuba imithi yamanje isiza ukulawula izifo, ingozi yokungazweli emishanguzweni kanye nemiphumela engemihle isalokhu ikhathaza. Sidinga imithi emisha ukuze siqondise igciwane kangcono.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Kunezinhlobo ezimbili zegciwane le- i-herpes simplex (herpes simplex) , uhlobo 1 (HSV-1) nohlobo 2 (HSV-2). I-HSV-1 ngokuvamile ibangela izifo emlonyeni kuyilapho i-HSV-2 ivame ukubangela izifo ezithweni zangasese. Zidluliselwa ngokuthintana ngqo nomuntu onegciwane. I-genital herpes ihlukaniswa njengesifo esithathelwana ngocansi. Ingase isabalale enganeni ngesikhathi sokubeletha. Ngemva kokutheleleka, amagciwane ahanjiswa ngemizwa yezinzwa aye emizimbeni yamangqamuzana ezinzwa, lapho ehlala khona impilo yonke. Izimbangela zokuphindaphinda zingabandakanya: ukuncipha kokusebenza kwamasosha omzimba, ingcindezi, nokuchayeka elangeni.
Ezimweni eziningi, izidakamizwa ezilwa namagciwane zithathwa kuphela uma izimpawu zinzima. Imithi elwa namagciwane yansuku zonke ingase inikezwe umuntu onesifo esivame kakhulu. Awukho umuthi wokugoma otholakalayo futhi umgomo we-shingles awuvimbeli i-herpes simplex. Ukwelashwa ngemithi elwa namagciwane njenge-aciclovir noma i-valaciclovir kunganciphisa ubukhali bezimpawu.
Amazinga omhlaba wonke we-HSV-1 noma i-HSV-2 aphakathi kuka-60% no-95% kubantu abadala. I-HSV-1 ivame ukungenwa ngesikhathi sobuntwana. Balinganiselwa ezigidini ezingama-536 abantu emhlabeni jikelele (u-16% wabantu) batheleleke nge-HSV-2 kusukela ngo-2003 ngamanani amakhulu phakathi kwabesifazane nalabo abasezweni elithuthukayo. Abantu abaningi abane-HSV-2 ababoni ukuthi banegciwane.
○ Ukwelashwa - Izidakamizwa ze-OTC
Gwema noma yikuphi ukuthintana ngokomzimba, njengokuqabula ingane, kuyilapho amabhamuza ekhona, njengoba ukuthintana kungasakaza ukutheleleka kwabanye abantu. Kufanele uphumule ngaphandle kokuphuza utshwala.
#Acyclovir cream